Illness: CIN grade 1 on cervical biopsy, is it serious? Description of disease: HPV18, 52 is positive, CIN grade 1 is cancer Hope to provide help: Is my problem serious, is it cancer? Is it curable and how to cure it? I am worried sick. First of all, according to the current result, it is only a mild precancerous lesion, not cervical cancer, so there is no need to worry. If there is no symptom, you can follow up regularly, and most patients can recover from CINI level, but you must communicate with your doctor to check on time. Cervical cancer is an infectious disease and the only malignant tumor with a clear etiology at present. Persistent infection with high-risk human papillomavirus (HPV), a small virus with more than 200 subtypes in its family, of which more than 40 can infect the genital tract, is the most important factor, and is classified into high-risk and low-risk types according to its relevance to cervical cancer and its precancerous lesions. High-risk types include 16, 18, 31, 33, 34, 35, 39, 45, 51, 52, 56, 58, 59, 66, etc., which are mainly present in cervical cancer and other anogenital cancers, and low-risk types include 6, 11, 42, 43 and 44, which are mainly seen in benign proliferative lesions such as genital warts. Low-risk HPV types 6 and 11 are associated with genital warts, while 70% of cervical cancers are associated with high-risk HPV types 16 and 18. HPV infection is common in the general population with a cumulative infection rate of up to 70%, but about 80% of infections are transient and the virus can be cleared by autoimmunity within 1 year, although a small proportion of women can develop cervical intraepithelial lesions, which also disappear with the clearance of the virus; 20% of high-risk HPV infections can persist and develop into different grades of intraepithelial lesions, which approximately 15 years on average before leading to the development of invasive cervical cancer. In fact, the peak age of HPV infection is between 18 and 30 years, while cervical cancer is more common in women over 35 years of age. In recent years, cervical cancer patients tend to be significantly younger, which is a serious threat to the health of women. Although the incidence of cervical cancer has been reduced by the common application of Pap smear screening at home and abroad, half of the patients with cytologic changes have already developed cervical cancer, and half of the cervical cancer patients occur in women who receive regular cytologic screening. The sensitivity of combined HPV screening for high-grade cervical intraepithelial lesions is 100%. Therefore, in many countries, the combination of HPV infection detection and cervical cytology is used for routine screening of cervical cancer in women over 30 years of age, with a sensitivity of 100%, a specificity of 92.5%, and a negative predictive value of almost 100%. In addition, cervical cancer is preventable, treatable, curable and eradicable. Two HPV preventive vaccines have been successfully marketed worldwide: Gardasil, a quadrivalent vaccine against HPV types 6/11/16/18, and Cervarix, a bivalent vaccine against HPV types 16/18, for the prevention of cervical cancer and its precancerous lesions and genital warts. As of today, these two vaccines are effective and safe for the vast majority of the vaccinated population, and more than 170 countries have introduced these two vaccines for the prevention of cervical cancer.